RPCEC00000366已完成2 期
A Phase II, sequential, multicenter, adaptive, parallel groups, randomized, placebo-controlled, double-blinded, to evaluate safety, reactogenicity and immunogenicity of the prophylactic vaccine candidate FINLAY-FR-1A anti SARS-CoV-2, in COVID-19 convalescents. (COVID-19) - SOBERANA PLUS
Finlay Vaccine Institute (FVI)0 个研究点开始时间: 2021年4月9日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Assignment: Parallel. Purpose: Prevention
入排标准
- 年龄范围
- 19 years 至 80 years（—）
- 性别
- All
入选标准
- •1. Subjects who give their written informed consent to participate in the study.
- •2. Subjects aged between 19 and 80 years.
- •3. Body mass index between 18.5 and 34.9 kg/m2 (obese persons grade I will be included).
排除标准
- •1. Subjects with a history of COVID-19 who meet any of the following criteria:
- •a) Current history of infection or having received a medical discharge for SARS-CoV 2 during the 2 months prior to recruitment.
- •b) History of severe clinical picture due to COVID-19, according to the medical history or obtained during the medical interview.
- •2. Subjects with acute febrile or infectious disease in the 7 days prior to the administration of the vaccine or at the time of its application.
- •3. Subjects with antimicrobial treatment or sustained treatment with NSAIDs in the 7 days prior to the administration of the vaccine.
- •4. Subjects with chronic non-communicable diseases that are NOT controlled, according to clinical or laboratory criteria established for each entity in the Cuban medical standards (Ex: bronchial asthma, chronic obstructive pulmonary disease, ischemic heart disease, arterial hypertension, diabetes mellitus, thyroid diseases, neurological and hemolymphopoietic diseases, liver failure, kidney failure, psychiatric illness at a psychotic level, among others).
- •5. Subjects with congenital or current acquired immune system disease.
- •6. Subjects with a history of neoplastic disease without full remission.
- •7. Subjects with a history of substance abuse in the past 30 days or substance addictive illness, except smoking.
- •8. Subjects with diminished mental faculties.
- •9. Subjects with a history of severe allergic disease (anaphylactic shock, angioneurotic edema, glottis edema, severe urticaria).
- •10. Subjects with a history of hypersensitivity to thiomersal.
- •11. Participation in another clinical trial of preventive or therapeutic intervention in the last 3 months.
- •12. Application of another vaccine in the last 30 days.
- •13. Treatment with immunomodulators in the last 30 days, eg; steroids (except for the occasional use of topical or inhaled steroids), cytostatics, interferon, immunoferon, transfer factor, monoclonal antibodies, biomodulin T, any ganmaglobulin, levamisole, heberferon, thymosin) or those who, due to their underlying disease, require treatment immunomodulator, which may coincide during the development of the study.
- •14. History of having received a blood transfusion or blood products in the last 3 months.
- •15. Subjects with difficulties in attending the planned follow-up consultations.
- •16. Splenectomy or splenic dysfunction.
- •17. Women of childbearing potential use safe contraceptive methods during the study.
- •18. Pregnancy, puerperium or lactation.
- •19. Subjects with tattoos in the deltoid region of both arms.
- •20. Subjects with positive results for: antibodies against HIV1 + 2, antibodies against hepatitis C, surface antigen of the hepatitis B virus and VDRL serology.
研究者
相似试验
进行中（未招募）
不适用
Phase II,multicenter,randomized,adaptive,double-blind,placebo controlled study to assess safety and efficacy of olexosime (TRO19622)in 3-25 year old Spinal Muscular Atrophy (SMA) patientsSpinal Muscular Atrophy - type II or III in non ambulant patients aged 3-25 yearsMedDRA version: 9.1Level: LLTClassification code 10032950EUCTR2010-020386-24-ITTROPHOS150
进行中（未招募）
1 期
Phase II, multicenter, randomized, adaptive, double-blind, placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients.EUCTR2010-020386-24-DETROPHOS SA150
进行中（未招募）
1 期
Safety and Efficacy of Olesoxime (TRO19622) in 3-25 yrs SMA patientsEUCTR2010-020386-24-GBTROPHOS SA165
进行中（未招募）
1 期
Phase II, multicenter, randomized, adaptive, double-blind, placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients.Spinal Muscular Atrophy (type 2 or type 3 non ambulant patients aged 3-25 years)MedDRA version: 12.1Level: LLTClassification code 10041582Term: Spinal muscular atrophyEUCTR2010-020386-24-FRTROPHOS SA
已完成
2 期
Phase II, multicenter, randomized, adaptive, double-blind,placebo controlled Study to assess Safety and Efficacy of olesoxime(TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patientsMedDRA - 12.1 LLT 10041582 Spinal Muscular AtrophyG12Spinal muscular atrophy and related syndromesDRKS00000814TROPHOS SA165